Barbara Troupin
Director/Board Member at EQUILLIUM, INC.
Net worth: - $ as of 2024-03-30
Profile
Barbara Troupin is an Independent Director at Equillium, Inc. She previously worked as Vice President-Medical Affairs at VIVUS, Inc. from 2006 to 2014, Chief Medical Officer & Senior Vice President at Apricus Biosciences, Inc. from 2015 to 2016, Chief Medical Officer & VP-Regulatory Affairs at Aquinox Pharmaceuticals, Inc. from 2016 to 2018, and Chief Medical Officer at Erx Pharmaceuticals, Inc. from 2018 to 2019.
She also served as Senior Vice President-Medical Affairs at MyoKardia, Inc. from 2020 to 2021.
Dr. Troupin received her undergraduate degree from the University of California San Diego, her MBA from The Wharton School of the University of Pennsylvania, and her doctorate from Perelman School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EQUILLIUM, INC.
-.--% | 2023-05-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
Barbara Troupin active positions
| Companies | Position | Start |
|---|---|---|
| EQUILLIUM, INC. | Director/Board Member | 2022-01-31 |
Former positions of Barbara Troupin
| Companies | Position | End |
|---|---|---|
| MYOKARDIA, INC. | Corporate Officer/Principal | 2021-02-28 |
| Erx Pharmaceuticals, Inc. | Chief Tech/Sci/R&D Officer | 2019-11-30 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 2018-06-30 |
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2016-05-30 |
| VIVUS, INC. | Chief Tech/Sci/R&D Officer | 2014-07-31 |
Training of Barbara Troupin
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Perelman School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EQUILLIUM, INC. | Health Technology |
| Private companies | 5 |
|---|---|
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| Erx Pharmaceuticals, Inc. |
- Stock Market
- Insiders
- Barbara Troupin
